

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1. (Currently amended) A composition comprising a protein in crystalline form wherein the protein consists of ~~SEQ ID No. 1~~ SEQ ID NO:1.
- 2 - 3. (Cancelled)
4. (Previously presented) A composition according to claim 1 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution greater than 3.0 Angstroms.
5. (Currently amended) A composition according to claim 1 wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, +/- 5%, of a=68.7 b=79.6 c=150.2, $\alpha=\beta=\gamma=90$.
6. (Canceled)
7. (Currently amended) A method comprising:
forming a crystallization volume comprising a precipitant solution and a protein consisting of ~~SEQ ID No. 1~~ SEQ ID NO:1; and
storing the crystallization volume under conditions suitable for crystal formation of the protein.
- 8 - 9 (Cancelled)
10. (Previously presented) A method according to claim 7 wherein a protein crystal is formed that diffracts X-rays for a determination of structure coordinates to a resolution greater than 3.0 Angstroms.

11. (Currently amended) A method according to claim 7 wherein a protein crystal is formed that has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, +/- 5%, of $a=68.7$ $b=79.6$ $c=150.2$, $\alpha=\beta=\gamma=90$.

12. (Canceled)

13. (Previously presented) A method according to claim 7, wherein a protein crystal is formed, the method further comprising diffracting the protein crystal to produce a diffraction pattern and solving the structure of the protein from the diffraction pattern.

14 - 16. (Cancelled)

17. (Withdrawn) The method according to claim 13, the method further comprising:
performing rational drug design using the solved structure; and
identifying an entity that associates with the protein crystal.

18. (Cancelled)

19. (Withdrawn) A method according to claim 17 wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and having-unit cell dimensions, +/- 5%, of $a=68.7$ $b=79.6$ $c=150.2$, $\alpha=\beta=\gamma=90$.

20. (Withdrawn) A method according to claim 13, the method further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

21. (Withdrawn) A method according to claim 13, the method further comprising measuring an activity of the protein when contacted with the one or more entities.

22. (Withdrawn) A method according to claim 13, the method further comprising comparing activity of the protein in a presence of and in the absence of the one or more entities;

and selecting entities where activity of the protein changes depending whether a particular entity is present.

23. (Withdrawn) A method according to claim 13, the method further comprising contacting cells expressing the protein with the one or more entities and detecting a change in a phenotype of the cells when a particular entity is present.

24. (New) A composition comprising a protein in crystalline form wherein the protein consists of SEQ ID NO:1 and wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, $\pm 5\%$, of $a=68.7$ $b=79.6$ $c=150.2$, $\alpha=\beta=\gamma=90$.